Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXYBOND vs OXYMORPHONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Oxymorphone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception and response. It also has affinity for kappa and delta opioid receptors.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Moderate to severe pain where an opioid analgesic is appropriate,Off-label: management of pain not responsive to non-opioid analgesics
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
Initial: 1 mg IV/IM every 3-4 hours as needed for moderate to severe pain; titrate to effect. For patient-controlled analgesia (PCA), 0.5 mg IV loading dose, then 0.25-0.5 mg every 6-15 minutes with lockout. Rectal suppository: 5 mg every 4-6 hours.
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Terminal elimination half-life: 7-9 hours (range 4-12 h in elderly/renal impairment). Clinically, steady-state achieved within 24-36 hours.
Primarily hepatic via CYP3A4 and to a lesser extent CYP2D6. Oxycodone is metabolized to noroxycodone (via CYP3A4), oxymorphone (via CYP2D6), and other minor metabolites.
For GFR 30-59 m L/min: reduce dose by 25% and increase dosing interval. For GFR <30 m L/min: reduce dose by 50% and administer every 12 hours. Avoid in ESRD.
Cr Cl 30-59: Administer 75% of normal dose; Cr Cl 15-29: Administer 50% of normal dose; Cr Cl <15: Avoid use or administer 25% of normal dose with extended dosing interval (e.g., every 6-8 hours).
Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression; Accidental Ingestion; Neonatal Opioid Withdrawal Syndrome; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants; and Risk of Medication Errors (due to immediate-release formulation, which requires careful dose conversion from other oxycodone products).
ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Avoid during labor due to respiratory depression in the newborn.
Opioid analgesics cross the placenta. First trimester: Limited data, but no clear evidence of major malformations; however, use associated with neural tube defects in some studies. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Use during labor may cause respiratory depression in the newborn.
ROXYBOND (oxycodone hydrochloride) is an immediate-release opioid agonist indicated for acute pain severe enough to require an opioid. Its unique formulation resists crushing and dissolution, but it can still be abused intravenously. Be aware of the risk of respiratory depression, particularly in opioid-naive patients. Use with caution in patients with respiratory disease, or in elderly or debilitated patients. Tolerance and dependence can develop; monitor for signs of misuse. Naloxone is the reversal agent. Not indicated for as-needed use; prescribe the lowest effective dose for the shortest possible duration.
Oxymorphone is approximately 10 times more potent than morphine. It has no ceiling effect for analgesia but dose-limiting adverse effects include respiratory depression and CNS depression. Use with extreme caution in patients with impaired renal function because the drug is primarily excreted unchanged in urine. Avoid use within 14 days of MAO inhibitor therapy. Monitor for opioid-induced constipation and consider prophylactic bowel regimen. For breakthrough pain, immediate-release formulations have an onset of 5-10 minutes intravenously and 15-30 minutes orally.
No interactions on record
No interactions on record
Common clinical questions about ROXYBOND vs OXYMORPHONE HYDROCHLORIDE, answered by our medical review team.
ROXYBOND is a Opioid Analgesic that works by ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.. OXYMORPHONE HYDROCHLORIDE is a Opioid Analgesic that works by Oxymorphone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception and response. It also has affinity for kappa and delta opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXYBOND and OXYMORPHONE HYDROCHLORIDE depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXYBOND is: Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.. The standard adult dose of OXYMORPHONE HYDROCHLORIDE is: Initial: 1 mg IV/IM every 3-4 hours as needed for moderate to severe pain; titrate to effect. For patient-controlled analgesia (PCA), 0.5 mg IV loading dose, then 0.25-0.5 mg every 6-15 minutes with lockout. Rectal suppository: 5 mg every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXYBOND and OXYMORPHONE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXYBOND is classified as Category C. ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chr. OXYMORPHONE HYDROCHLORIDE is classified as Category C. Opioid analgesics cross the placenta. First trimester: Limited data, but no clear evidence of major malformations; however, use associated with neural tube defects in some studies.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Primarily hepatic via glucuronidation (UGT2B7) to oxymorphone-3-glucuronide; minor CYP450 involvement (CYP3A4 and CYP2C9).
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Primarily renal (90% as parent drug and metabolites); <1% fecal. Unchanged oxymorphone accounts for ~30% of urinary recovery.
Approximately 20–30%, primarily to albumin.
Approximately 10-12%; primarily bound to albumin.
2.6–4.0 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, liver).
Vd: 1.5-3.7 L/kg; indicates extensive tissue distribution (e.g., brain, adipose). Higher Vd may require dose adjustment in obese patients.
Oral: 10–20% (extensive first-pass metabolism); intranasal: 30–50%; intravenous: 100%.
Oral (immediate-release): 10-15% (extensive first-pass metabolism); Oral (extended-release): 10-15%; Intramuscular: equivalent to IV (100% relative to IV but with slower absorption).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and increase interval. Child-Pugh Class C: avoid use.
Child-Pugh Class A: No adjustment necessary; Child-Pugh Class B: Reduce initial dose by 50% and titrate cautiously; Child-Pugh Class C: Avoid use or administer 25% of normal dose with prolonged interval.
Weight-based dosing: 0.1-0.2 mg/kg/dose every 4-6 hours as needed. Maximum single dose: 5 mg for <50 kg, 10 mg for ≥50 kg.
Not FDA-approved for pediatric use. Limited data: IV/IM 0.1-0.2 mg/kg every 4-6 hours as needed (max 3 mg/dose).
Start at lowest effective dose (2.5-5 mg every 4-6 hours). Titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor renal function.
Initiate at 0.5-1 mg IV/IM every 4-6 hours; titrate slowly. Consider 50% dose reduction due to increased sensitivity and risk of respiratory depression.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Respiratory depression; CNS depression; addiction potential; hypotension; seizures; increased intracranial pressure; biliary tract disease; pancreatitis; severe renal impairment; elderly and debilitated patients; adrenal insufficiency; severe hepatic impairment; concurrent use with MAOIs or serotonergic drugs.
Hypersensitivity to oxymorphone or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected paralytic ileus; gastrointestinal obstruction; postpartum analgesia (for the injection form).
Avoid alcohol and any alcohol-containing foods or beverages. Grapefruit and grapefruit juice may increase oxycodone levels; avoid concurrent use.
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, increasing oxymorphone levels and risk of adverse effects. Alcohol should be strictly avoided due to additive CNS depression and increased risk of respiratory depression. No other clinically significant food interactions are reported.
Small amounts of oxycodone are excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 3:1. Use with caution, especially in mothers who are ultrarapid metabolizers of CYP2D6, as this increases risk of toxicity in the infant. Monitor infant for drowsiness, poor feeding, and respiratory depression.
Oxymorphone is excreted into breast milk. M/P ratio not determined. The American Academy of Pediatrics considers it compatible with breastfeeding, but monitor infant for signs of respiratory depression and sedation. Use lowest effective dose for shortest duration.
Pregnancy may increase oxycodone clearance due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed: consider increasing the frequency or dose based on pain control and tolerance. Avoid high doses near term; use lowest effective dose. Monitor for respiratory depression in both mother and neonate.
Pregnancy increases volume of distribution and clearance. Dose requirements may increase by 20-50% in the second and third trimesters to achieve same analgesic effect. Titrate to effect and monitor for maternal respiratory depression. Postpartum, reduce dose to prepregnancy levels.
Take exactly as prescribed; do not break, crush, chew, or dissolve the tablet as it can cause rapid release and fatal overdose.,Do not consume alcohol or any alcohol-containing products while taking ROXYBOND.,Store securely out of sight and reach of children and pets; properly dispose of unused tablets via a drug take-back program.,Side effects include constipation, nausea, dizziness, and drowsiness; contact your healthcare provider if you experience difficulty breathing or extreme sleepiness.,Avoid driving or operating heavy machinery until you know how ROXYBOND affects you.,Do not share this medication with others; it can cause addiction and death.,Inform your doctor about all other medications, especially sedatives, tranquilizers, or antidepressants.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or break extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of fatal respiratory depression.,Do not stop abruptly; withdrawal symptoms may occur. Work with your provider to taper if needed.,Store securely out of reach of children and others. Dispose of unused medication via take-back programs.,Report any signs of respiratory depression (slow/shallow breathing), severe sedation, or constipation immediately.,This medication may impair your ability to drive or operate machinery. Do not perform such tasks until you know how it affects you.,Inform all healthcare providers that you are taking this medication.,If you are pregnant, plan to become pregnant, or are breastfeeding, discuss risks with your doctor.,Avoid grapefruit and grapefruit juice while taking oxymorphone as it may increase side effects.